Ceribell Unveils AI EEG Platform Targeting Acute Care Seizure Detection
Reuters
Dec 03, 2025
<a href="https://laohu8.com/S/CBLL">Ceribell</a> Unveils AI EEG Platform Targeting Acute Care Seizure Detection
Ceribell Inc. has released a corporate presentation detailing recent developments in its AI-powered point-of-care EEG platform, designed for the detection and management of serious neurological conditions in acute care settings. The presentation highlights a U.S. annual addressable market estimated at over $2 billion and reports third-quarter 2025 revenue of $22.6 million, representing a 31% year-over-year increase. As of the end of the third quarter, Ceribell has 615 active accounts and achieved an 88% gross margin. The platform targets the diagnosis of both visible and non-convulsive seizures, particularly in critically ill patients where such conditions are often underdiagnosed. The content also addresses the limitations of conventional EEG systems in acute care and emphasizes the importance of timely seizure detection and intervention. You can access the full presentation through the link below.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ceribell Inc. published the original content used to generate this news brief on December 03, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.